Alvotech Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Robert Wessman

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	98.3%
CEO görev süresi	2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Robert Wessman'un ücretlendirmesi Alvotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$441m
Jun 30 2024	n/a	n/a	-US$618m
Mar 31 2024	n/a	n/a	-US$494m
Dec 31 2023	US$2m	US$1m	-US$552m
Sep 30 2023	n/a	n/a	-US$596m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$713m
Dec 31 2022	US$740k	n/a	-US$514m

Tazminat ve Piyasa: Robert 'nin toplam tazminatı ($USD 1.52M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.20M ).

Tazminat ve Kazançlar: Robert şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Robert Wessman (54 yo)

2yrs

Görev süresi

US$1,517,000

Tazminat

Mr. Robert Wessman serves as Chief Executive Officer of Alvotech since January 1, 2023. He Founded Alvotech in 2013 and serves as its Executive Chairman and Member of the Board of Directors since January 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Wessman	CEO, Founder & Executive Chairman	2yrs	US$1.52m	Veri yok
Faysal Kalmoua	COO & Director	1.3yrs	Veri yok	0% € 0
Joel Morales	Chief Financial Officer	4.9yrs	Veri yok	0.032% € 1.2m
Giedrius Zunda	Chief Technical Officer	no data	Veri yok	Veri yok
Joseph McClellan	Chief Scientific Officer	5.3yrs	Veri yok	0.051% € 2.0m
Benedikt Stefansson	VP of Investor Relations and Global Communications	no data	Veri yok	Veri yok
Tanya Zharov	General Counsel	2yrs	Veri yok	0% € 0
Jenny Steingrimsdottir	Vice President of People & Culture	less than a year	Veri yok	Veri yok
Anil Okay	Chief Commercial Officer	6.5yrs	Veri yok	Veri yok
Ming Li	Chief Strategy Officer	5yrs	Veri yok	Veri yok
Christina Siniscalchi	Chief Quality Officer	less than a year	Veri yok	Veri yok
Anthony Maffia	Chief Regulatory Affairs Officer	1yr	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: Z45 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Wessman	CEO, Founder & Executive Chairman	6yrs	US$1.52m	Veri yok
Faysal Kalmoua	COO & Director	4.6yrs	Veri yok	0% € 0
Hjorleifur Palsson	Director	no data	Veri yok	Veri yok
Linda McGoldrick	Independent Non-Executive Director	2.6yrs	US$81.00k	0.0035% € 134.9k
Lisa Graver	Non-Executive Director	2.6yrs	US$71.00k	0.0035% € 134.9k
Tomas Ekman	Non-Executive Director	6yrs	Veri yok	Veri yok
Arni Hardarson	Non-Executive Director	2.6yrs	Veri yok	Veri yok
Richard Davies	Independent Non-Executive Deputy Chairman	6yrs	US$156.00k	0.35% € 13.4m
Ann Merchant	Independent Non-Executive Director	2.6yrs	US$113.00k	0.0035% € 134.9k

3.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: Z45 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/21 18:05
Gün Sonu Hisse Fiyatı	2025/01/21 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Alvotech 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Balaji Prasad	Barclays
Balaji Prasad	Barclays
Peter Verdult	Citigroup Inc

Alvotech Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Alvotech Appoints Hjörleifur Pálsson as Director

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Executive Changes

Alvotech Announces Changes to the Leadership Team

Less than half of directors are independent

Alvotech, Annual General Meeting, Jun 06, 2023

Recent updates

Alvotech to Report Q2, 2025 Results on Aug 14, 2025

Third quarter 2024 earnings released: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for Avt05, A Proposed Biosimilar to Simponi (Golimumab)

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Forecast breakeven date pushed back to 2026

New minor risk - Financial position

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$2.43 loss per share (vs US$2.60 loss in FY 2022)

Alvotech Announces Executive Changes

New minor risk - Share price stability

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Less than half of directors are independent

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Alvotech to Report Q1, 2023 Results on May 18, 2023

Less than half of directors are independent

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$2.60 loss per share (vs US$0.92 loss in FY 2021)

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Investor sentiment improves as stock rises 23%

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Investor sentiment improved over the past week

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Third quarter 2022 earnings released

Less than half of directors are independent

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

Alvotech to Report Nine Months, 2022 Results on Nov 15, 2022

Alvotech Announces Executive Changes

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech Reports Update on Initial AVT02 Biologics License Application